Windlas Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026, and recommendation of dividend

Related-party transactionsResults View source PDF Explain this filing

WINDLAS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.3%Reaction day

₹782.00

prior close

₹784.10

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-0.3% vs market

Pharmaceuticals peers, median of 164sector-0.1%-0.2% vs sector

On the reaction day the stock moved 0.3 pts less than Nifty Microcap 250 and 0.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.6

10m

-1.4

15m

-1.3

30m

-1.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.3+0.1-0.3-0.1-0.2

Next day

+0.3+1.7-1.4+0.9-0.6

+4.9+2.4+2.5+0.9+4.0

+5.0+2.4+2.6+0.7+4.3

+5.7+1.7+4.0+0.8+4.9

+4.1+0.6+3.5+0.0+4.1

+2.7+1.9+0.8-0.1+2.8

15d

+4.9+4.9-0.0+1.0+3.8

+8.8+8.9-0.1+3.0+5.8

+11.1+7.5+3.5+4.4+6.6

+26.3+13.6+12.7+7.9+18.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Windlas Biotech reported audited standalone and consolidated financial results for FY ended March 31, 2026. Consolidated revenue grew 19.0% to Rs. 9,040.89 million from Rs. 7,598.78 million, driven by the pharmaceutical business segment. Profit after tax (PAT) increased 9.0% to Rs. 664.56 million from Rs. 609.94 million. EBITDA (operating profit before working capital changes) stood at Rs. 1,237.16 million, with finance costs at Rs. 48.26 million and depreciation at Rs. 307.43 million. The Board recommended a dividend of Rs. 6.30 per share (126% on face value of Rs. 5). The auditors, J C Bhalla & Co, issued an unmodified (clean) opinion on both standalone and consolidated results with no qualifications. Key corporate actions included a share buyback of 470,000 shares at Rs. 1,000 per share (Rs. 470 million) completed in April 2026, and the dissolution of Windlas Inc., USA as a subsidiary effective March 31, 2026. ESOP expenses surged to Rs. 166.11 million from Rs. 24.60 million due to the new Windlas Plan 2025.

Likely market impact

Revenue growth of ~19% is strong but slightly below the 20% threshold, and PAT growth of 9% is below the 25% threshold — neither flag meets high-growth thresholds. The clean audit opinion, healthy operating cash flow of Rs. 1,049 million, and low debt-to-equity ratio (~0.05) are positive. The large Rs. 470 million buyback signals confidence but reduces equity. Dividend of Rs. 6.30/share reflects shareholder-friendly intent.